Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1925 1
1934 1
1935 1
1937 1
1939 1
1943 1
1946 1
1951 2
1953 2
1968 1
1970 1
1976 1
1977 2
1982 1
1986 3
1987 5
1988 4
1989 5
1990 1
1992 1
1995 2
1996 6
1997 3
1998 2
1999 3
2001 1
2002 1
2003 3
2005 5
2006 3
2007 2
2008 5
2009 11
2010 9
2011 2
2012 4
2013 2
2014 3
2015 5
2016 5
2017 7
2018 18
2019 7
2020 5
2021 6
2022 13
2023 19
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Jastreboff AM, et al. Among authors: haupt a. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26. N Engl J Med. 2023. PMID: 37366315 Clinical Trial.
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. Coskun T, et al. Among authors: haupt a. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. Mol Metab. 2018. PMID: 30473097 Free PMC article. Clinical Trial.
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M; GZGI Investigators. Wharton S, et al. Among authors: haupt a. N Engl J Med. 2023 Sep 7;389(10):877-888. doi: 10.1056/NEJMoa2302392. Epub 2023 Jun 23. N Engl J Med. 2023. PMID: 37351564 Clinical Trial.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. Coskun T, et al. Among authors: haupt a. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9. doi: 10.1016/j.cmet.2022.07.013. Epub 2022 Aug 18. Cell Metab. 2022. PMID: 35985340 Free article.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Rosenstock J, et al. Among authors: haupt a. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385280 Clinical Trial.
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, Wiese RJ, Tuttle KR, Cherney DZI. Heerspink HJL, et al. Among authors: haupt a. Lancet Diabetes Endocrinol. 2022 Nov;10(11):774-785. doi: 10.1016/S2213-8587(22)00243-1. Epub 2022 Sep 21. Lancet Diabetes Endocrinol. 2022. PMID: 36152639 Clinical Trial.
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z. Heise T, et al. Among authors: haupt a. Lancet Diabetes Endocrinol. 2022 Jun;10(6):418-429. doi: 10.1016/S2213-8587(22)00085-7. Epub 2022 Apr 22. Lancet Diabetes Endocrinol. 2022. PMID: 35468322 Clinical Trial.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. Urva S, et al. Among authors: haupt a. Lancet. 2022 Nov 26;400(10366):1869-1881. doi: 10.1016/S0140-6736(22)02033-5. Epub 2022 Oct 27. Lancet. 2022. PMID: 36354040 Clinical Trial.
Mitochondrial complexome reveals quality-control pathways of protein import.
Schulte U, den Brave F, Haupt A, Gupta A, Song J, Müller CS, Engelke J, Mishra S, Mårtensson C, Ellenrieder L, Priesnitz C, Straub SP, Doan KN, Kulawiak B, Bildl W, Rampelt H, Wiedemann N, Pfanner N, Fakler B, Becker T. Schulte U, et al. Among authors: haupt a. Nature. 2023 Feb;614(7946):153-159. doi: 10.1038/s41586-022-05641-w. Epub 2023 Jan 25. Nature. 2023. PMID: 36697829 Free PMC article.
176 results